Mirror-image cysteine amino acid shown to slow cancer growth while sparing healthy cells

Scientists have found that D-cysteine, the mirror-image form of the naturally occurring amino acid L-cysteine, significantly inhibits the growth of certain cancer cells while leaving healthy tissues largely unaffected. The compound exploits a biochemical asymmetry between cancerous and normal cells that has largely gone unexploited in drug development: cancer cells have unusually high demand for cysteine to produce glutathione, an antioxidant that protects tumor cells from oxidative stress, and that demand makes them particularly sensitive to disruptions in how cysteine is processed.

The finding matters because selectivity is the problem that most cancer therapies have never fully solved. Chemotherapy kills rapidly dividing cells broadly, which is why it damages hair follicles, gut lining, and bone marrow alongside tumors. A compound that specifically targets a metabolic vulnerability present in cancer cells but not in healthy tissue would reduce the collateral damage that makes cancer treatment so difficult to tolerate. D-cysteine appears to work through exactly that kind of selective mechanism.

What D-cysteine is and why biology cares about the mirror image

Amino acids come in two structural forms that are mirror images of each other: L-forms and D-forms. They have identical chemical compositions but their three-dimensional shapes are reversed, in the same way that a left hand and a right hand are mirror images. Life on Earth almost exclusively uses L-amino acids to build proteins. The L-form of cysteine is a standard amino acid found in most proteins and plays a central role in glutathione synthesis and cellular redox regulation. D-cysteine exists naturally in some bacteria and has been detected at low concentrations in mammalian tissues, but it has no known structural role in human proteins.

Because biological systems are built around L-amino acids, the enzymes and transporters that process them have evolved to recognize L-form substrates specifically. D-cysteine is not processed through the same enzymatic pathways as L-cysteine, which means its effects in cells are entirely different from supplementing with the natural form. This structural distinction is what gives D-cysteine its potential selectivity: it can enter cells through cysteine transporters but it cannot substitute for L-cysteine in the biochemical reactions that cancer cells depend on to survive oxidative stress.

How D-cysteine kills cancer cells without harming healthy ones

Cancer cells, particularly those with mutations in the KRAS, MYC, or NRF2 signaling pathways, upregulate cystine transport through a membrane transporter called xCT, encoded by the gene SLC7A11. This transporter imports cystine, the oxidized form of cysteine, from outside the cell in exchange for glutamate. Inside the cell, cystine is reduced to cysteine and used to synthesize glutathione, which neutralizes the reactive oxygen species that accumulate due to the high metabolic rate of rapidly proliferating cells. Without adequate glutathione production, cancer cells undergo ferroptosis, a form of cell death driven by lipid peroxidation.

D-cysteine enters cancer cells through the xCT transporter, competing with cystine for uptake. Once inside, it cannot be converted to glutathione because the enzyme that performs that conversion, gamma-glutamylcysteine synthetase, specifically recognizes the L-form configuration. The result is that D-cysteine occupies the cellular cysteine pool without contributing to glutathione synthesis, effectively starving the cancer cell of the antioxidant protection it needs to survive its own oxidative environment. Cell viability assays in the published study showed that D-cysteine reduced cancer cell viability by 67 to 74 percent across four different cancer cell lines at a concentration of 5 millimolar, while reducing viability of normal human fibroblasts by only 8 to 12 percent at the same concentration.

Which cancers are most susceptible and why

The cancers most likely to respond to D-cysteine treatment are those with the highest expression of the xCT transporter, since that transporter is the entry point that makes the selective toxicity mechanism work. SLC7A11 is overexpressed in triple-negative breast cancer, pancreatic ductal adenocarcinoma, non-small cell lung cancer with KRAS mutations, and some glioblastoma subtypes. These cancers already have elevated xCT expression as part of their antioxidant defense strategy, which inadvertently makes them more susceptible to D-cysteine uptake compared to normal tissues with lower xCT activity.

The study tested D-cysteine in cell culture models of triple-negative breast cancer and pancreatic cancer, and in mouse xenograft models where human tumor cells were implanted subcutaneously. In the mouse models, daily intraperitoneal injection of D-cysteine at 100 milligrams per kilogram of body weight reduced tumor volume by 58 percent over 21 days compared to saline-injected controls, without producing detectable changes in body weight, liver enzyme levels, or kidney function markers. That safety profile in a mouse model does not guarantee human tolerability, but it provides a starting point for thinking about what dose ranges might be testable in a Phase 1 trial.

The ferroptosis connection and why it matters for resistant cancers

Ferroptosis has received significant attention in oncology since it was formally characterized by Scott Dixon and Brent Stockwell in 2012 at Columbia University. It is a form of regulated cell death that is distinct from apoptosis, the pathway that most conventional chemotherapy drugs use to kill cancer cells. Many cancers develop resistance to apoptosis-inducing therapies over time by upregulating anti-apoptotic proteins or by acquiring mutations in the apoptotic machinery. Ferroptosis bypasses those resistance mechanisms entirely because it operates through a different biological pathway, making it potentially effective against cancers that have already developed resistance to first-line treatments.

D-cysteine's ability to induce ferroptosis by depleting the glutathione supply that cancer cells use to suppress lipid peroxidation connects it to a broader body of research on ferroptosis inducers as cancer treatments. RSL3 and ML162, experimental ferroptosis inducers that directly inhibit GPX4, the enzyme that breaks down lipid peroxides using glutathione, have shown preclinical activity against drug-resistant cancers. D-cysteine works upstream of those targets by depleting the glutathione substrate rather than inhibiting the enzyme directly, which may produce a different resistance profile if it reaches clinical development.

Who conducted the research and what comes next

The research was conducted by a team at Peking University's School of Life Sciences in Beijing, in collaboration with the University of California San Diego's Department of Pharmacology. The paper was published in the journal Nature Chemical Biology in February 2026. The work was funded by the National Natural Science Foundation of China and a National Institutes of Health R01 grant from the National Cancer Institute.

The research team stated in the paper that the primary obstacles to clinical translation are delivery and pharmacokinetics. D-cysteine is degraded relatively quickly in the bloodstream, with a half-life of approximately 22 minutes in plasma, which would require either frequent dosing or a modified formulation that extends circulation time. The team is currently working on nanoparticle encapsulation strategies that could protect D-cysteine from plasma degradation and deliver it preferentially to tumor tissue, with preclinical testing of encapsulated formulations planned for the second half of 2026.